Psoriasis is a chronic, inflammatory, and immune mediated dermatological diseases that adversely affects the quality of life of millions of individuals worldwide. Due to its heterogeneous natüre, which varies from patient to patient, and its systemic manifestations, current treatment approaches are often insufficient and make disease management challenging. This complex pathophysiology has increasingly highlighted the need for more targeted and effective drug delivery systems beyond conventional therapeutic strategies. In recent years, nanotechnology-based drug delivery strategies have attracted attention in psoriasis treatment due to their potential to offer more effective pharmacodynamic profiles and reduce undesirable systemic effects. Among these, microemulsion systems are considered innovative delivery platforms thanks to their high stability, ability to penetrate biological barriers, and controlled release properties. Recent preclinical studies have demonstrated that these formulations can significantly enhance anti-inflammatory, immunomodulatory, and antiproliferative effects. This review aims to evaluate therapeutic potential, formulation techniques, pharmaceutical performance, and translational possibilities of microemulsion-based delivery systems considering preclinical studies published between 2019 and 2024.
Saylam et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: